InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Public ClinicalTrials.gov record NCT05463796. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer. * The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal. * The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.
Study identification
- NCT ID
- NCT05463796
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 5,000 participants
Conditions and interventions
Conditions
- Cancer Risk
- Cancer Predisposition Syndrome
- Hereditary Cancer Prediction
- Childhood Cancer Survivors
- Adult Cancer Survivors
- IARC Carcinogens
- Smoking History
- Lung Cancer
- Ductal/Lobular Carcinoma
- Barrett Esophagus
- Pancreatic Precursor Lesions
- Colonic Dysplasia/Adenomata
- Non-Alcoholic Fatty Liver Disease
- Non Alcoholic Steatohepatitis
- Cirrhosis
- High Grade Prostatic Epithelial Neoplasia
- High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ
- Adenomatous Hyperplasia
- High-risk Oral Precancerous Diseases
- Melanocytic Lesion, Adult
- Hematologic Malignancy
- Lung; Node
- Serous Tubal Intraepithelial Carcinoma
- Endometrial Intraepithelial Neoplasia
- Cervical and Endocervical Carcinoma in Situ
- Vulvar Intraepithelial Neoplasia
- Nephrogenic Rests
- Benign Bone Lesions With Risk of Malignant Degeneration
- Giant Cell Tumor
- Osteochondroma
- Spitz Nevus
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 24, 2023
- Primary completion
- Mar 24, 2030
- Completion
- Mar 24, 2031
- Last update posted
- Aug 16, 2026
2023 – 2031
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05463796, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 16, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05463796 live on ClinicalTrials.gov.